Advances in precision diagnosis and treatment of cholangiocarcinoma
10.12092/j.issn.1009-2501.2025.02.002
- VernacularTitle:胆管癌精准诊疗进展及前沿
- Author:
Zhenmei CHEN
1
;
Jinhong CHEN
1
Author Information
1. 复旦大学附属华山医院普外科肝胆外科中心,上海 200040
- Publication Type:Journal Article
- Keywords:
cholangiocarcinoma;
targeted thera-py;
immunotherapy;
precision diagnosis and treat-ment
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2025;30(2):159-170
- CountryChina
- Language:Chinese
-
Abstract:
Cholangiocarcinoma(CCA)is a highly aggressive and heterogeneous biliary malignancy characterized by challenges in early diagnosis,limit-ed efficacy of traditional chemotherapy,and poor prognosis.Due to its significant heterogeneity at the genomic,epigenetic,and molecular levels,mo-lecular testing and targeted therapy have become increasingly important in CCA management,form-ing an integral part of the era of precision oncolo-gy.The development of next-generation sequenc-ing(NGS)has advanced research into the molecu-lar subtypes and therapeutic targets of CCA,includ-ing FGFR2 fusions/rearrangements,IDH1 muta-tions,and BRAF mutations.Recently,two phase Ⅲ clinical trials,TOPAZ-1 and KEYNOTE-966,have es-tablished the pivotal role of immunotherapy com-bined with chemotherapy in advanced CCA.While precision diagnosis and treatment in CCA have shown promising progress,this field remains in its exploratory phase and faces numerous challenges.This review summarizes recent advancements in the diagnosis,molecular targeted therapy,immuno-therapy,resistance mechanisms,and the develop-ment of novel strategies for CCA.
